Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
Condition: Malaria Infection Interventions: Drug: M5717 60 mg; Drug: Pyronaridine; Drug: Atovaquone-Proguanil; Drug: M5717 200 mg; Drug: M5717 660mg Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials